Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/4952f086-e4b1-4121-9d4c-7a03804e8078/
SUDEEPPHRM
SUDEEP PHARMA LIMITEDSnapshot 2026-06-07 · 0.0w · Fresh
Strategy Eligibility
0 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
3.0%ile
P/E
56.4×
P/S
15.1×
P/B
12.5×
E/P
0.0177
FCF Yield
-0.002
EBITDA/EV
0.025
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
98.00000000
/100 — 1=cheapest
VC2 (Trending Value)
97.00000000
/100
VC3 (Buyback)
98.00000000
/100
P/E of 56.4x is premium-priced — the market is paying up for expected growth. Negative FCF yield (-0.2%) — the business is currently cash-consumptive. VC2 score of 97.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
74.0%ile
ROE
0.222
ROA
0.164
Net Margin
0.267
Op Margin
0.338
GPA
0.386
Current
2.65
F-Score
5/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.094
Earn Growth
0.041
Accruals
0.111
lower=better
5yr Consist
No
ROE of 22% is exceptional. Accruals ratio of 0.111 is elevated — earnings quality may be lower than headline numbers suggest.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
41.0%ile
6M Return
13.7%
Vol 252d
43.9%
Vol 60d
31.8%
↓ Contracting
Max DD 12M
-29.4%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
OS
Composite & Factor Heatmap
All factors at a glance
0.12
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare
· 160 peers
Sector Value %ile
8.7%
Sector Quality %ile
56.5%
P/E z-score
-0.10
P/B z-score
1.47
Sector Avg OS
43.9%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
| Symbol | Name | OS | Value | Quality | Momentum |
|---|---|---|---|---|---|
| NATCOPHARM | 98.0% | 88.0% | 87.0% | 81.0% | |
| UNIVPHOTO | 97.0% | 86.0% | 74.0% | 94.0% | |
| LINCOLN | 97.0% | 88.0% | 80.0% | 81.0% | |
| STAR | 96.0% | 73.0% | 91.0% | 91.0% | |
| VENUSREM | 96.0% | 68.0% | 94.0% | 99.0% | |
| HALEOSLABS | 95.0% | 82.0% | 77.0% | 81.0% | |
| AUROPHARMA | 94.0% | 71.0% | 84.0% | 87.0% | |
| SPARC | 93.0% | 72.0% | 86.0% | 83.0% |
Factor Interactions
Earnings Quality Concern
ROE looks strong (22%) but high accruals (0.111) suggests earnings are accrual-heavy, not cash-backed.
Quality at a Premium
High quality (74th) but expensive (3th value). Upside may be limited without earnings growth.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
6.9% avg (7 factors)
Quality
B
74.9% avg (7 factors)
Momentum
C
54.7% avg (1 factors)
Risk
D
43.5% avg (1 factors)
High quality business commanding a premium price. The market recognises the quality — returns from here depend on continued fundamental execution. Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
| Factor | Current | Streak | Trend | Spark |
|---|---|---|---|---|
| OS Composite | 0.120 | —1 | — | |
| Value %ile | 0.030 | —1 | — | |
| Quality %ile | 0.740 | —1 | — | |
| Momentum %ile | 0.410 | —0 | — | |
| F-Score | 5.000 | —0 | — | |
| Confidence | 0.758 | —1 | — | |
| Volatility | 0.439 | —1 | — |
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
56.39
Earnings Yield (E/P)
0.0177
Price / Sales
15.08
Price / Book
12.51
Price / Cash Flow
174.89
FCF Yield
-0.2%
EBITDA / EV
2.5%
Sales Yield (1/P·S)
0.0656
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
22.2%
Return on Assets
16.4%
Net Margin
26.7%
Operating Margin
33.8%
Gross Profit / Assets
Novy-Marx GPA
38.6%
Current Ratio
2.65
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.111
MomentumPrice trend strength over different horizons
6M Return
13.7%
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
9.4%
Earnings Growth (YoY)
4.1%
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
5
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
98
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
97
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
98
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity